Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its RFS and DMFS endpoints in resected stage IIB-IV melanoma, the first positive Phase 3 result for an individualized neoantigen therapy.
The U.S. FDA grants market approval for Moderna’s mFLUSIVA (mRNA-1010) seasonal flu vaccine in adults 50+. Review Phase 3 trial data, efficacy, and rollout details.
Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst [Read More…]
Moderna’s new mRNA (messenger Ribonucleic Acid) flu shot completed the phase 3 trials with succeeding data. They are aiming to launch in early 2024. The flu vaccine – mRNA-1010 has produced an immune response against all four A and B strains – A/H1N1, A/H3N2, influenza B/Yamagata, and B/Victoria.
